BioWorld Asia

Feb. 7, 2007

Push By AstraZeneca Includes COPD Deal Worth Up To $500M

LONDON - AstraZeneca plc went through a hyperactive round last week of licensing and acquisitions, sealing deals worth $650 million. (BioWorld International) Read More

Circassia Raises £6M To Move Its Allergenic Products Ahead

Study Confirms Prion Protein As Therapeutic Target In CJD

ScanBalt Promoting Baltic Biotechnology Cooperation

AstraZeneca Buys Antiviral Firm Arrow For $150M Cash

Jerini Extends Pact With Baxter For New Hemophilia Drugs

NicOx Details Offer To Raise €130M

No Abstract Read More

Europe Moves Ahead On Advanced Therapy Rules

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 8, 2026.

ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

BioWorld

If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...